However, there was a considerable improvement in NT-pro BNP in patients with LVEF > 40%, and a recent worsening heart failure event with ARNI compared to Valsartan in the PARAGLIDE-HF trial [13]. The gene discussed is NPPB; the disease is hydrops fetalis.